Immunoadsorption in pemphigus

Autoimmunity

Volumn 39, Issue 7, 2006, Pages 609-616

  Eming, Rüdiger ^a   Hertl, Michael ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Autoantibodies; IgG; Immunoadsorption; Pemphigus

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CYCLOPHOSPHAMIDE; DESMOCOLLIN; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLAKOGLOBIN; PREDNISOLONE; RITUXIMAB;

ADJUVANT THERAPY; ANEMIA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BACTERIAL INFECTION; BRADYCARDIA; CLINICAL TRIAL; DESMOSOME; DISEASE SEVERITY; DRUG MEGADOSE; HERPES GESTATIONIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; NONHUMAN; PARESTHESIA; PATHOGENICITY; PATIENT SAFETY; PEMPHIGOID; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REMISSION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOANTIBODIES; DESMOGLEIN 3; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; PEMPHIGUS; RECEPTORS, IGE;

EID: 33751077503     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600972040     Document Type: Article

References (46)

1. Hertl, M.(2005) Pemphigus. In Autoimmune bullous skin disorders. (pp. 45-70). Cambridge, MA: Springer Science+Business Media.
2. Schiltz, JR and (1976) Production of acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum J Invest Dermatol, 67, pp. 254-260.
3. Farb, RM and (1978) Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase Proc Natl Acad Sci USA, 75, pp. 459-463.
4. Anhalt, GJ and (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease N Engl J Med, 306, pp. 1189-1196.
5. Stanley, JR. (1993) Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion Adv Immunol, 53, pp. 291-325.
6. Amagai, M. (2003) Desmoglein as a target in autoimmunity and infection J Am Acad Dermatol, 48(2), pp. 244-252.
7. Grando, SA. (2006) Cholinergic control of epidermal cohesion Exp Dermatol, 15, pp. 265-282.
8. Fiebiger, E and (1998) Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship J Clin Invest, 101(1), pp. 243-251.
9. Calkins, CC and (2006) Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies J Biol Chem, 281(11), pp. 7623-7634.
10. Arredondo, J and (2005) Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus Am J Pathol, 167(6), pp. 1531-1544.
11. Grando, SA. (2000) Autoimmunity to keratinocyte acetylcholine receptors in pemphigus Dermatology, 201, pp. 290-295.
12. Garrod, DR and (2002) Desmosomal cadherins Curr Opin Cell Biol, 14(5), pp. 537-545.
13. Koch, PJ and (1997) Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris J Cell Biol, 137, pp. 1091-1102.
14. Amagai, M and (1994) Adsorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (desmoglein 3) produced by baculovirus J Clin Invest, 94, pp. 59-67.
15. Amagai, M and (2000) Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus J Clin Invest, 105, pp. 625-631.
16. Tsunoda, K and (2003) Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3 J Immunol, 170(4), pp. 2170-2178.
17. Cheng, SW and (2002) Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 Br J Dermatol, 147(2), pp. 261-265.
18. Komai, A and (2001) The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay Br J Dermatol, 144(6), pp. 1177-1182.
19. Sekiguchi, M and (2001) Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins J Immunol, 167(9), pp. 5439-5448.
20. Anzai, H and (2004) Conformational epitope mapping of antibodies against desmoglein 3 in experimental murine pemphigus vulgaris J Dermatol Sci, 35(2), pp. 133-142.
21. Nguyen, VT and (2000) Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions J Clin Invest, 106(12), pp. 1467-1479.
22. Nguyen, VT and (1998) The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus Arch Dermatol, 134(8), pp. 971-980.
23. Nguyen, VT and (2000) Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity Am J Pathol, 157(4), pp. 1377-1391.
24. Nguyen, VT and (2000) Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine J Biol Chem, 275(38), pp. 29466-29476.
25. Braun, N and Bosch, T. (2000) Immunoadsorption, current status and future developments Expert Opin Investig Drugs, 9(9), pp. 2017-2038.
26. Hershko, AY and Naparstek, Y. (2005) Removal of pathogenic autoantibodies by immunoadsorption Ann N Y Acad Sci, 1051, pp. 635-646.
27. Nakaji, S. (2001) Current topics on immunoadsorption therapy Ther Apher (4), pp. 301-305.
28. Asahi, T and (2003) Blood purification therapies using dextran sulfate cellulose columns liposorber and selesorb Ther Apher Dial, 7(1), pp. 73-77.
29. Ronspeck, W and (2003) Peptide based adsorbers for therapeutic immunoadsorption Ther Apher Dial, 7(1), pp. 91-97.
30. Wallukat, G and (2002) Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy N Engl J Med, 347(22), pp. 1806.
31. Cotterill, JA and (1978) Plasma exchange in the treatment of pemphigus vulgaris Br J Dermatol, 98(2), pp. 243.
32. Lüftl, M and (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber Br J Dermatol, 149(3), pp. 598-605.
33. Schmidt, E and (2003) Protein A immunoadsorption: A novel and effective adjuvant treatment of severe pemphigus Br J Dermatol, 148(6), pp. 1222-1229.
34. Shimanovich, I and (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption Clin Exp Dermatol. [Epub ahead of print]
35. Eming, R and (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption Dermatology, 212(2), pp. 177-187.
36. Psaridi-Linardaki, L and (2005) Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy J Neuroimmunol, 159(1,2), pp. 183-191.
37. Herrero-Gonzalez, JE and (2006) Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients Eur J Immunol, 36(4), pp. 1039-1048.
38. Eming R, et al. Longterm efficacy of immunoadsorption, rituximab as a monotherapy or sequential therapy in recalcitrant pemphigus. (in preparation).
39. Zillikens D, et al. Recommendations for use of immunopheresis in the treatment of autoimmune bullous diseases. (submitted).
40. Schmaldienst, S and (2001) Intravenous immunoglobulin application following immunoadsorption: Benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford), 40(5), pp. 513-521.
41. Pfütze, M and Introducing a novel autoimmune bullous skin disorder score (ABSIS) for pemphigus Eur J Dermatol. (in revision)
42. Schoen, H and (1998) Immunapheresis in paraneoplastic pemphigus Arch Dermatol, 134, pp. 706-710.
43. Frost, N and (2005) Treatment of pemphigus vulgaris with protein A immunoadsorption. Case report of long-term history showing favourable outcome Ann NY Acad Sci, 1051, pp. 591-596.
44. Herrero-González, JE and (2005) Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption Clin Exp Dermatol, 30, pp. 519-522.
45. Wöhrl, S and (2003) Pemphigoid gestationis: Treatment with immunoapheresis J Dtsch Dermatol Ges, 1, pp. 126-130.
46. Niedermeier, A and (2006) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies) Arch Dermatol. (in revision)